Stock Track | Verona Pharma Soars 7.36% on Strong Ohtuvayre Sales and Positive Clinical Trial Progress

Stock Track

02-27

Shares of Verona Pharma plc (NASDAQ: VRNA) soared 7.36% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales momentum for its newly launched COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.

According to the financial report, net sales of Ohtuvayre reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024, marking a successful launch for the company's first commercial product. Verona Pharma also initiated two Phase 2 trials in Q3 2024, evaluating nebulized ensifentrine in combination with glycopyrrolate for COPD and in patients with bronchiectasis.

The company plans to start a Phase 2b trial in the second half of 2025 to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine and glycopyrrolate for COPD treatment. Additionally, Verona Pharma is progressing regulatory activities for potential marketing authorization applications for Ohtuvayre in the European Union and the UK.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1108141824"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108141824\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1108141824?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 23:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108141824","market":"us","top_or_hot":-1,"title":"Stock Track | Verona Pharma Soars 7.36% on Strong Ohtuvayre Sales and Positive Clinical Trial Progress","media":"Stock Track","content":"<p>Shares of Verona Pharma plc (NASDAQ: VRNA) soared 7.36% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales momentum for its newly launched COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.</p>\n\n<p>According to the financial report, net sales of Ohtuvayre reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024, marking a successful launch for the company's first commercial product. Verona Pharma also initiated two Phase 2 trials in Q3 2024, evaluating nebulized ensifentrine in combination with glycopyrrolate for COPD and in patients with bronchiectasis.</p>\n\n<p>The company plans to start a Phase 2b trial in the second half of 2025 to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine and glycopyrrolate for COPD treatment. Additionally, Verona Pharma is progressing regulatory activities for potential marketing authorization applications for Ohtuvayre in the European Union and the UK.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Verona Pharma Soars 7.36% on Strong Ohtuvayre Sales and Positive Clinical Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Verona Pharma Soars 7.36% on Strong Ohtuvayre Sales and Positive Clinical Trial Progress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-27 23:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Verona Pharma plc (NASDAQ: VRNA) soared 7.36% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales momentum for its newly launched COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.</p>\n\n<p>According to the financial report, net sales of Ohtuvayre reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024, marking a successful launch for the company's first commercial product. Verona Pharma also initiated two Phase 2 trials in Q3 2024, evaluating nebulized ensifentrine in combination with glycopyrrolate for COPD and in patients with bronchiectasis.</p>\n\n<p>The company plans to start a Phase 2b trial in the second half of 2025 to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine and glycopyrrolate for COPD treatment. Additionally, Verona Pharma is progressing regulatory activities for potential marketing authorization applications for Ohtuvayre in the European Union and the UK.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRNA","symbol_name":"維羅納製藥","start_time":0,"source_url":"","article_id":"1108141824","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108141824","pubTimestamp":1740668925,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Verona Pharma plc  soared 7.36% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales momentum for its newly launched COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.According to the financial report, net sales of Ohtuvayre reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024, marking a successful launch for the company's first commercial product. Verona Pharma also in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRNA":"维罗纳制药"},"translate_title":"股票赛道Verona Pharma因Ohtuvayre销售强劲和临床试验进展积极而飙升7.36%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRNA":1},"content_text":"Shares of Verona Pharma plc (NASDAQ: VRNA) soared 7.36% in pre-market trading on Thursday, following the company's fourth quarter and full-year 2024 financial results that showed strong sales momentum for its newly launched COPD drug Ohtuvayre and progress in its Phase 2 clinical trials.\nAccording to the financial report, net sales of Ohtuvayre reached $36.6 million in Q4 2024 and $42.3 million for the full year 2024, marking a successful launch for the company's first commercial product. Verona Pharma also initiated two Phase 2 trials in Q3 2024, evaluating nebulized ensifentrine in combination with glycopyrrolate for COPD and in patients with bronchiectasis.\nThe company plans to start a Phase 2b trial in the second half of 2025 to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine and glycopyrrolate for COPD treatment. Additionally, Verona Pharma is progressing regulatory activities for potential marketing authorization applications for Ohtuvayre in the European Union and the UK.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}